PRPaul Rivest

Paul Rivest

*This is an algorithmically generated author record based on publicly available information.

Paul Rivest has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Completion Rates of Treatment for Latent Tuberculosis Infection in Quebec, Canada From 2006 to 2010

    by Paul Rivest, Maria-Constanza Street, Robert Allard

    Treatment of latent TB infection (LTBI) in high-risk populations has been identified as a priority activity for reducing TB incidence. Treatment completion rates are usually far from the 80% target. The objective of this study was to evaluate the proportion of individuals who obtained enough medication for standard LTBI treatment.


  • Open Access

    Tuberculosis and homelessness in Montreal: a retrospective cohort study

    by Jason Tan de Bibiana, Carmine Rossi, Paul Rivest, Alice Zwerling, Louise Thibert, Fiona McIntosh, Marcel A Behr, Dick Menzies, Kevin Schwartzman

    Background: Montreal is Canada's second-largest city, where mean annual tuberculosis (TB) incidence from 1996 to 2007 was 8.9/100,000. The objectives of this study were to describe the epidemiology of TB among homeless persons in Montreal and assess patterns of transmission and sharing of key locations. Methods: We reviewed demographic, clinical, and microbiologic data for all active TB cases reported in Montreal from 1996 to 2007 and identified persons who were homeless in the year prior to TB diagnosis. We genotyped all available Mycobacterium tuberculosis isolates by IS6110 restriction fragment length polymorphism (IS6110-RFLP) and spoligotyping, and used a geographic information system to identify potential locations for transmission between persons with matching isolates. Results: There were 20 cases of TB in homeless persons, out of 1823 total reported from 1996-2007. 17/20 were Canadian-born, including 5 Aboriginals. Homeless persons were more likely than non-homeless persons to have pulmonary TB (20/20), smear-positive disease (17/20, odds ratio (OR) = 5.7, 95% confidence interval (CI): 1.7-20), HIV co-infection (12/20, OR = 14, 95%CI: 4.8-40), and a history of substance use. The median duration from symptom onset to diagnosis was 61 days for homeless persons vs. 28 days for non-homeless persons (P = 0.022). Eleven homeless persons with TB belonged to genotype-defined clusters (OR = 5.4, 95%CI: 2.2-13), and ten potential locations for transmission were identified, including health care facilities, homeless shelters/drop-in centres, and an Aboriginal community centre. Conclusions: TB cases among homeless persons in Montreal raise concerns about delayed diagnosis and ongoing local transmission.


  • Trends in Duration of Hospitalization for Patients with Tuberculosis in Montreal, Canada from 1993 to 2007

    by Kianoush Dehghani, Robert Allard, Jean Gratton, Louise Marcotte, Paul Rivest

    Objective: To study the trend of hospital stays for patients diagnosed with pulmonary TB in Montreal from 1993 to 2007. Methods: From the registry of hospital discharge summary information, we selected first hospitalizations for patients with a diagnosis of TB, and from the reportable diseases registry, patients with culture positive pulmonary TB. We linked the selected cases, using the first 3 characters of postal code of residence, sex and age. From the linked cases, we included those for whom date of patient’s admission to hospital (from the former registry) was similar to the date of notification to the public health department (from the latter registry), while allowing for an appropriate variation. Results: Among the 563 linked cases, the median duration of hospitalization was 17.0 days. Duration of hospitalization did not significantly decrease during the study period. Cases with positive sputum smear were more likely to stay in hospital ≥14 days compared to those without one (OR=1.90, 95% CI: 1.34–2.70). TB cases ≥50 years of age remained in hospital longer than those between 18-49 years of age (OR=1.66, 95% CI: 1.15–2.40). Conclusion: For 63.9% (360) of the cases studied, the duration of hospitalization was ≥14 days, which is consistent with the minimum recommended hospital stay for patients with pulmonary TB in Canada. Further studies are necessary to examine the impact of discharging hospitalized TB patients before 14 days of hospital stay on the risk of TB transmission in the community. Objectifs: Évaluer la durée de séjour hospitalier des patients avec tuberculose pulmonaire à Montréal de 1993 à 2007. Méthode: Dans le fichier des données hospitalières, nous avons sélectionné des patients hospitalisés pour la première fois pour une tuberculose pulmonaire et, du fichier des maladies à déclaration obligatoire, des patients avec résultat positif à la culture des expectorations. Nous avons relié les cas sélectionnés avec les trois premiers caractères du code postal de résidence, le sexe et l’âge. Parmi les cas reliés, nous avons gardé ceux dont la date d’admission (tirée du premier fichier) était similaire jusqu’à un certain point à la date de déclaration à la direction de santé publique (tirée du deuxième fichier). Résultats: Parmi les 563 cas retenus, la durée médiane d’hospitalisation était 17,0 jours. La durée d’hospitalisation n’a pas diminué significativement durant la période étudiée. Les cas avec frottis des expectorations positif avaient plus de risque de rester à l’hôpital ≥14 jours que les cas avec frottis négatif (Ratio de cotes[RC]=1,90; Intervalle de confiance [IC] à 95%: 1,34–2,70). Les cas ≥50 ans avaient plus de risque de rester à l’hôpital longtemps que les cas âgés de 18 à 49 ans (RC=1,66; IC 95%: 1,15–2,40). Conclusion: Pour 63,9 % (360) des cas étudiés, la durée d’hospitalisation était ≥14 jours et conforme avec la durée minimale recommandée au Canada pour les patients avec tuberculose pulmonaire. D’autres recherches sont nécessaires pour évaluer l’impact de donner congé de l’hôpital avant les 14 jours recommandés à des patients avec tuberculose pulmonaire sur le risque de transmission de la maladie dans la communauté.


  • Varicella Vaccination for Grades 4 and 5 Students

    by Paul Rivest, Lise Grenier, Guy Lonergan, Lucie Bédard

    In 2002–2003, as part of a pilot project, varicella vaccination was offered to susceptible students in grades 4 and 5 in schools whose health services are provided by a local community services centre in Montréal. This immunization campaign was merged with the hepatitis B immunization programme.


  • Hospitalisations for gastroenteritis: the role of rotavirus

    by Paul Rivest, Mélanie Proulx, Guy Lonergan, Marc H Lebel, Lucie Bédard


    • 15 February 2004
      • Vol. 30  (4) , 29-33, 36

    Difficulties associated with pertussis surveillance.

    by P Rivest, F Richer, L Bédard

  • Open Access

    Initial Drug Regimen for Active Tuberculosis Cases in Montreal, 1995‐1998

    by Paul Rivest, Terry N Tannenbaum

    OBJECTIVES: To evaluate the proportion of tuberculosis (TB) cases initially treated with the recommended four‐drug regimen of isoniazid (INH), rifampin (RIF), pyrazinamide (PZA) and ethambutol (EMB) or streptomycin; and to identify factors associated with the choice of initial therapy.DESIGN: Descriptive analysis of surveillance data obtained by TB case notifications from physicians and microbiology laboratories.SETTING: The island of Montreal (with a population of 1,854,435 people).STUDY POPULATION: All TB cases reported between January 1, 1995 and December 31, 1998.OUTCOME MEASURE: The proportion of TB cases initially treated with a four‐drug regimen by sex, age, country of birth, site of disease and year of reporting.MAIN RESULTS: Seven hundred forty‐one cases were reported during the study period. Among the 687 analyzed cases, 406 (59.1%) received the recommended initial four‐drug regimen (INH‐RIF‐PZA‐EMB), 187 (27.2%) received an INH‐RIF‐PZA regimen, 61 (8.9%) received an INH‐RIF‐EMB regimen and 33 (4.8%) received an INH‐RIF regimen only. In a logistical regression model, a four‐drug regimen was significantly associated with respiratory disease (odds ratio [OR] 4.48; 95% CI 3.15 to 6.39), age younger than 65 years (OR 2.32; 95% CI 1.55 to 3.45), being foreign‐born (OR 1.62; 95% CI 1.06 to 2.48) and later year of reporting (OR 1.27; 95% CI 1.09 to 1.47).CONCLUSIONS: The proportion of TB cases initially treated with a four‐drug regimen has increased steadily since 1995, reaching 65% in 1998. However, given the rate of INH resistance in Montreal, efforts to promote the use of the initial four‐drug regimen must continue.

  • Open Access

    Severe Complications Associated with Varicella: Province of Quebec, April 1994 to March 1996

    by Paul Rivest, Lucie Bédard, Louise Valiquette, Elaine Mills, Marc H Lebel, Gilles Lavoie, John Carsley

    OBJECTIVE: To determine the frequency and severity of serious complications associated with varicella in Quebec; the frequency and severity of cases of congenital varicella; and hospital costs associated with hospitalizations for varicella.STUDY DESIGN:All hospitalizations related to varicella were identified through the use of a hospital data bank and pertinent data were collected from hospital records.SETTING:Province of Quebec with a population of 6,895,960 people.STUDY POPULATION:All cases with a principal or secondary diagnosis of varicella hospitalized in Quebec between April 1, 1994 and March 31, 1996.OUTCOME MEASURES:Types of complications and reason for hospitalization, risk of complications and calculation of associated costs were studied.RESULTS:Nine hundred nine eligible hospitalizations were identified between April 1, 1994 and March 31, 1996. In all, 583 (64.1%) hospitalizations were for the treatment of complications, 127 (14.0%) for administration of intravenous acyclovir and 199 (21.9%) for supportive care. Healthy people accounted for 644 (70.8%) hospitalizations and immunosuppressed individuals for 136 (15.0%). Among children, one-half of the principal complications were skin infections, while 13.5% and 8.4% of principal complications were pneumonia and neurological complications, respectively. Among adults, the most common complication was pneumonia, with a rate of 43.5%, followed by thrombocytopenia and skin infections, with rates of 22.2% and 14.8%, respectively. The complication rate was 29.2 cases/10,000 cases of varicella.CONCLUSIONS:Although perceived as a benign childhood disease by the general population, varicella may be accompanied by severe complications. Morbidity associated with varicella is one of the elements that must be considered when evaluating the usefulness of varicella vaccine.